CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Carfilzomibdrug
Likely dose
Carfilzomib 20 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01775930
NCT01775930Phase 2Completed
CompareCT.gov

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma

M.D. Anderson Cancer Center·interventional·Posted Jan 25, 2013·Updated Mar 4, 2020

In Brief

A Phase 2 clinical trial evaluating Carfilzomib for Kidney Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The goal of this clinical research study is learn if carfilzomib can help control kidney cancer. The safety of this drug will also be studied. Carfilzomib is designed to block cancer cells from repairing themselves. If the cancer cells cannot repair themselves, this may cause them to die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsOnyx Therapeutics, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2013
Enrollment StartOct 1, 2013
Primary CompletionJan 18, 2019
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 13.4 years ago

Interventions

Carfilzomibdrug

20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.